This forum is for hepatitis patients, family members, loved ones, friends or anyone with an interest in hepatitis, to have open social conversations about any topic they choose, with the exception of religion and politics. Please note that our standard “Rules for Posting in Public Areas”, which are found in our
Terms of Use , also apply in this community.
If you are newly diagnosed with Hepatitis or you have questions or information to share about current treatments, research studies, clinical trials, or other medical issues pertaining to Hepatitis, please post it in one of our Hepatitis Communities (
Hep A ,
Hep B ,
Hep C or
Hep-autoimmune ).
See:
http://www.natap.org/2006/HCV/041906_02.htm
Figure one has a graphic that demonstrates the difference. Unfortunately, although the mechanism is poorly understood, this discrepancy is widely accepted.
Best of luck to you,
Bill
Take care—
Bill
Seriously, a lot of my griping about HCV patent rights and all the $ spent on PIs and 'cocktails' goes back to my gut feeling that any funding pulled away from understanding and deveoping IFN is a distraction.
Racial disparity in liver disease: Biological, cultural, or socioeconomic factors.
Nguyen GC, Thuluvath PJ.
Chronic liver diseases are a major public health issue in the United States, and there are substantial racial disparities in liver cirrhosis-related mortality. Hepatitis C virus (HCV) is the most significant contributing factor in the development of chronic liver disease, complications such as hepatocellular carcinoma, and the need for liver transplantation. In the United States, African Americans have twice the prevalence of HCV seropositivity and develop hepatocellular carcinoma at more than twice the rate as whites. African Americans are, however, less likely to respond to interferon therapy for HCV than are whites and have considerably lower likelihood of receiving liver transplantation, the only definitive therapy for end-stage liver disease. Even among those who undergo transplantation, African Americans have lower 2-year and 5-year graft and patient survival compared to whites. We will review these racial disparities in chronic liver diseases and discuss potential biological, socioeconomic, and cultural contributions. An understanding of their underlying mechanisms is an essential step in implementing measures to mollify racially based inequities in the burden and management of liver disease in an increasingly racially and ethnically diverse population.
PMID: 18302296 [PubMed - indexed for MEDLINE]
Interesting; if I read you correctly, you feel that IFN is promising enough alone to continue refinement without necessarily adding additional adjunctive therapy? I treat with a large, reputable HCV research and clinical establishment here in California, and I get a lukewarm response re: PI meds from the docs there. Rather ho-hum attitude compared to the fuss I read in here. There doesn’t seem to be much doubt left to me that these will at least be equally as important as an adjunctive as riba was to the original IFN monotherepy. I’d be interested to hear more on this from you—
Bill
http://www.hepcaustralia.com.au/index.php/information/hep-c-information-station/46-hep-c-information-station/606-the-necessity-of-seeing-a-specialist-for-hepatitis-c
Meanwhile, it's been six years. Where's our pegylated Infergen? Where is a finalized dosing schedule for Albuferon? Why has no one tried hooking a branched PEG molecule onto IFN alpha 2b? And these are just the observations of a casual observer with a HIgh School diploma. What about the truly innovative developments within our grasp, such as race, gender, or genotype specific tx drugs?
It would seem that the 'cocktail' driven approach, adding a third and possibly fourth med into the mix, will be more profitable for those developing them - in the short term. I think a better understanding of IFN and what it can do may be more profitable for all of us in the long run.
Have a great day.
Trish
Bill
Bill
Medicmommy, you made some good musings, as usual that I could appreciate. The answers to the racial disparity have not yet been answered, so your guess is as good or better than mine. The latest study was done in the US and printed March of 2008, that's the one I posted. The one prior to that, I think it was done in 2006 but I could be wrong about that one, that information is from the article Bill posted. It seems that they are no closer to knowing the reason for the racial disparity biologically speaking than they were in the past. There's nothing wrong with your logic on a global scale, however the study was done in the US where most AA's are not from Africa. Also I don't see why the study researchers even mention the socioeconomic factors as those would be fairly obvious no matter what color a person is. I've also read that Asians do better out of all other races, could it be their diet? And could the disparity between AA's and CA's be diet as well? Maybe we will find out someday, what really matters is that all ppl get tx no matter of their color or socioeconomic status. God Bless